@article {167091,
	title = {Subconjunctival bevacizumab for vascularized rejected corneal grafts.},
	journal = {Journal of cataract and refractive surgery},
	volume = {33},
	year = {2007},
	month = {2007 Nov},
	pages = {1991-3},
	abstract = {<p>We describe 3 patients who experienced corneal neovascularization following keratoplasty and were treated with a single subconjunctival injection of 2.5 mg bevacizumab. Although there was immediate regression of the corneal vascularization and haze, as well as improvement in the anterior chamber reaction, the effects were short-lived and starting from the second week, the corneal vessels began to progress. All 3 cases ended in permanent graft failure. The series suggests a possible role for bevacizumab in the management of graft rejection with vascularization.</p>
},
	keywords = {Angiogenesis Inhibitors, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Bevacizumab, Conjunctiva, Corneal Neovascularization, Graft Rejection, Humans, Injections, Keratoplasty, Penetrating, Male, Middle Aged, Vascular Endothelial Growth Factor A},
	issn = {0886-3350},
	doi = {10.1016/j.jcrs.2007.07.012},
	author = {Ahmed Awadein}
}
